EEG alpha power as an intermediate measure between brain-derived neurotrophic factor Val66Met and depression severity in patients with major depressive disorder

Journal of Clinical Neurophysiology

Volumn 30, Issue 3, 2013, Pages 261-267

  Zoon, Harriët F A ^a   Veth, C P M ^a,b   Arns, Martijn ^a,c   Drinkenburg, W H I M ^d   Talloen, Willem ^d   Peeters, Pieter J ^d   Kenemans, J L ^c  

^a RESEARCH INSTITUTE BRAINCLINICS   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alpha rhythm; Brain derived neurotrophic factor; Depression; EEG; Val66Met polymorphism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALPHA RHYTHM; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NETHERLANDS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84879853438     PISSN: 07360258     EISSN: 15371603     Source Type: Journal    
DOI: 10.1097/WNP.0b013e3182933d6e     Document Type: Article

References (48)

1. Arns M, Peters S, Breteler R, Verhoeven L. Different brain activation patterns in dyslexic children: evidence from EEG power and coherence patterns for the double-deficit theory of dyslexia. J Integr Neurosci 2007;6: 175-190.
2. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7: 137-151.
3. Bruder GE, Tenke CE, Warner V, et al. Electroencephalographic measures of regional hemispheric activity in offspring at risk for depressive disorders. Biol Psychiatry 2005;57: 328-335.
4. Bruder GE, Sedoruk JP, Stewart JW, et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry 2008;63: 1171-1177.
5. Castren E. Is mood chemistry? Nat Rev Neurosci 2005;6: 241-246.
6. Czira ME, Wersching H, Baune BT, Berger K. Brain-derived neurotrophic factor gene polymorphisms, neurotransmitter levels, and depressive symptoms in an elderly population. Age 2011;34: 1529-1541.
7. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59: 1116-1127.
8. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112: 257-269.
9. Enoch MA, Xu K, Ferro E, et al. Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 2003;13: 33-41.
10. Enoch MA, White KV, Waheed J, Goldman D. Neurophysiological and genetic distinctions between pure and comorbid anxiety disorders. Depress Anxiety 2008;25: 383-392.
11. Frank E, Cassano GB, Rucci P, et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011;41: 151-162.
12. Gatt JM, Kuan SA, Dobson-Stone C, et al. Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol Psychol 2008;79: 275-284.
13. Gordon E, Cooper N, Rennie C, et al. Integrative neuroscience: the role of a standardized database. Clin EEG Neurosci 2005;36: 64-75.
14. Gottesman II, Gould TD. The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions. Am J Psychiatry 2003;160: 636-645.
15. Gratton G, Coles MG, Donchin E. A new method for off-line removal of ocular artefact. Electroencephalogr Clin Neurophysiol 1983;55: 468-484.
16. Grin-Yatsenko VA, Baas I, Ponomarev VA, Kropotov JD. EEG power spectra at early stages of depressive disorders. J Clin Neurophysiol 2009;26: 401-406.
17. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007;12: 1079-1088.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23: 56-62.
19. Hegerl U, Wilk K, Olbrich S, et al. Hyperstable regulation of vigilance in patients with major depressive disorder. World J Biol Psychiatry 2012;13: 436-446.
20. Itil TM. The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG). Prog Neurobiol 1983;20: 185-249.
21. Jiang X, Xu K, Hoberman J, et al. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 2005;30: 1353-1361.
22. Katz LC, Shatz CJ. Synaptic activity and the construction of cortical circuits. Science 1996;274: 1133-1138.
23. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Brain Res Rev 1999;29: 169-195.
24. MacKinnon DP, Lockwood CM, Hoffman JM, et al. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods 2002;7: 83-104.
25. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3: 2011-2030.
26. Molendijk ML, Bus BA, Spinhoven P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011;16: 1088-1095.
27. Niedermeyer E. Alpha rhythms as physiological and abnormal phenomena. Int J Psychophysiol 1997;26: 31-49.
28. Ozan E, Okur H, Eker C, et al. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull 2010;81: 61-65.
29. Pae CU, Masand PS, Peindl K, et al. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim Care Companion J Clin Psychiatry 2008;10: 205-210.
30. Pollock VE, Schneider LS. Quantitative, waking EEG research on depression. Biol Psychiatry 1990;27: 757-780.
31. Raichle ME, Gusnard DA. Intrinsic brain activity sets the stage for expression of motivated behavior. J Comp Neurol 2005;493: 167-176.
32. Romei V, Rihs T, Brodbeck V, Thut G. Resting electroencephalogram alphapower over posterior sites indexes baseline visual cortex excitability. Neuroreport 2008;19: 203-208.
33. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163: 1905-1917.
34. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64: 527-532.
35. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20): 22-33; quiz 34-57.
36. Smit DJ, Posthuma D, Boomsma DI, Geus EJ. Heritability of background EEG across the power spectrum. Psychophysiology 2005;42: 691-697.
37. Spronk D, Arns M, Barnett KJ, et al. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J Affect Disord 2011;128: 41-48.
38. Sullivan PF, Neal MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157: 1552-1562.
39. Thomason ME, Yoo DJ, Glover GH, Gotlib IH. BDNF genotype modulates resting functional connectivity in children. Front Hum Neurosci 2009;3: 1-10.
40. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurementbased care. Neuropsychopharmacology, 2007;32: 2479-2489.
41. Van Beijsterveldt CE, Molenaar PC, de Geus EJ, Boomsma DI. Heritability of human brain functioning as assessed by electroencephalography. Am J Hum Genet 1996;58: 562-573.
42. Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010;15: 260-271.
43. Vogel F. The genetic basis of the normal human electroencephalogram (EEG). Hum Genet 1970;10: 91-114.
44. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45: 742-747.
45. Williams LM, Rush AJ, Koslow SH, et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 2011;12: 4.
46. Winterer G, Mahlberg R, Smolka MN, et al. Association analysis of exonic variants of the GABA b-receptor gene and alpha electroencephalogram voltage in normal subjects and alcohol-dependent patients. Behav Genet 2003;33: 7-15.
47. Wolkowitz OM, Wolf J, Shelly W, et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35: 1623-1630.
48. Zou YF, Ye DQ, Feng XL, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010;20: 535-544.